Newsfeeds - Spark Newswire

4 minute read

AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know

Today, 6:42 PM

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.

ALNY

12 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 9, 2022

By Benzinga Insights

Today, 6:42 PM

Upgrades

ADCT

6 minute read

Bluebird bio Seeks Back-to-Back Nods, ‘Go’ or ‘No-Go’ For Revance’s Botox Rival, Amylyx’ Twin Hurdles And More: September’s Key PDUFA Catalysts Biotech Investors Must Know

By Shanthi Rexaline

Today, 6:42 PM

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

ACAD

34 minute read

Earnings

Earnings Scheduled For August 4, 2022

By Benzinga Insights

Today, 6:42 PM

Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.

AAOI

1 minute read

PayPal, SoFi Technologies And Some Other Big Stocks Moving Higher In Today’s Pre-Market Session

By Lisa Levin

Today, 6:42 PM

PayPal Holdings, Inc. (NASDAQ: PYPL) rose 12% to $100.35 in pre-market trading after the company reported better-than-expected Q2 results and raised FY22 EPS guidance.

FFIE

4 minute read

Biotech Investors: August’s Key PDUFA Catalysts You Must Know

By Shanthi Rexaline

Today, 6:42 PM

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.

ACAD

2 minute read

Uncategorized

Short Volatility Alert: Amicus Therapeutics, Inc.

By Christopher Sappo

Today, 6:42 PM

On Tuesday, shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) experienced volatile short activity. After the activity, the stock price went up +5.67% to $9.88. The overall sentiment for FOLD has been Bearish.

FOLD

5 minute read

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

By Shanthi Rexaline

Today, 6:42 PM

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and Drug Administration approved by May 2021.

ACAD

1 minute read

Amicus Therapeutics Q1 EPS $(0.30) Misses $(0.25) Estimate, Sales $78.72M Beat $77.13M Estimate

By Benzinga Newsdesk

Today, 6:42 PM

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.25) by 20 percent. This is a 20 percent decrease over losses of $(0.25) per share from

FOLD

16 minute read

Earnings Scheduled For May 9, 2022

By Benzinga Insights

Today, 6:42 PM

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

ACM